Search

Your search keyword '"Rohrer, T."' showing total 226 results
Start Over Author "Rohrer, T."
226 results on '"Rohrer, T."'

5. Assoziation zwischen dem Risiko einer diabetischen Ketoazidose und der regionalen Inzidenz von COVID-19-Fällen und Todesfällen bei Kindern und Jugendlichen mit neu aufgetretenem Typ-1-Diabetes während der ersten Welle der Pandemie in Deutschland

Author

Kamrath, C, additional, Rosenbauer, J, additional, Eckert, A, additional, Pappa, A, additional, Reschke, F, additional, Rohrer, T, additional, Mönkemöller, K, additional, Wurm, M, additional, Hake, K, additional, Raile, K, additional, and Holl, RW, additional

Published
2021
Full Text
View/download PDF

15. Long-Term Studies Contribute Disproportionately to Ecology and Policy (vol 67, pg 271, 2017)

Author

Hughes, BB, Beas-Luna, R, Barner, AK, Brewitt, K, Brumbaugh, DR, Cerny-Chipman, EB, Close, SL, Coblentz, KE, De Nesnera, KL, Drobnitch, ST, Figurski, JD, Focht, B, Friedman, M, Freiwald, J, Heady, KK, Heady, WN, Hettinger, A, Johnson, A, Karr, KA, Mahoney, B, Moritsch, MM, Osterback, A-MK, Reimer, J, Robinson, J, Rohrer, T, Rose, JM, Sabal, M, Segui, LM, Shen, C, Sullivan, J, Zuercher, R, Raimondi, PT, Menge, BA, Grorud-Colvert, K, Novak, M, and Carr, MH

Subjects
Ecology, Biological Sciences, Environmental Sciences
Published
2017

17. Interaction of Pubertal Development and Metabolic Control in Adolescents with Type 1 Diabetes Mellitus

Author

Plamper, M., Gohlke, B., Woelfle, J., Konrad, K., Rohrer, T., Hofer, S., Bonfig, W., Fink, K., Holl, R. W., Plamper, M., Gohlke, B., Woelfle, J., Konrad, K., Rohrer, T., Hofer, S., Bonfig, W., Fink, K., and Holl, R. W.

Abstract

Background. In T1DM, delayed pubertal development and reduced final height are associated with inadequate metabolic control. Objective. To assess whether T1DM affects pubertal growth spurt and whether metabolic control during puberty is gender-related. Methods. Using a large multicentre database, longitudinal data from 1294 patients were analysed. Inclusion criteria: complete records of height and HbA1c from the age of seven to 16 years. Exclusion criteria: other significant chronic diseases and medications, T1DM duration less than three months, and initial BMI < 3rd or > 97th percentile. Results. Growth velocity (GV) was impaired with a significant reduction of peak GV by 1.2 cm in boys. HbA1c increase during male puberty was lower except for a period of 1.5 years. The highest HbA1c increase in boys coincided with maximum growth spurt. In girls, the highest HbA1c increase was observed during late puberty. Even though there is impaired GV, both sexes reach a height at 16 years of age which corresponds to the background population height. Conclusion. Worsening of metabolic control is sex-discordant and associated with gender-specific alterations of GV. However, the vast majority of boys and girls with T1DM seems to reach normal height at the age of 16 years.

Published
2017

19. Effectiveness and Safety of rhIGF-1 Therapy in Children: The European Increlex® Growth Forum Database Experience

Author

Bang, P, Polak, M, Woelfle, J, Houchard, A, Hausler, G, Zwiauer, K, Adiceam, P, Carla Malpuech, H, Cessans, C, Cogne, M, Colle, M, Coutant, R, Houang, M, Lienhardt, A, Mallet, E, Nicolino, M, Petrus, M, Tauber, Mt, Wagner, K, Weill, J, Akkurt, I, Bechtold, S, Bierkamp Christophersen, D, Blanke, Jg, Bonfig, W, Doerr, Hg, Frühwald, M, Hartmann, K, Hauffa, B, Holterhus, Pm, Hübner, A, Ittner, J, Jourdan, C, Keller, A, Kim Berger HS, Köster, B, Krüger, J, Land, C, Leichter, H, Lorenzen, F, Meissner, T, Mohnike, K, Morlot, M, Müller, H, Ockert, C, Rohrer, T, Pankau, R, Partsch, Cj, Schönau, E, Schwab, K, Simic Shleicher, G, Tittel, B, Bernasconi, S, Cannavo', Salvatore, Cappa, M, Cavallo, L, Cherubini, V, Chiumello, G, Citro, G, Concolino, D, Perri, P, Lampis, A, Maghnie, M, Perrone, L, Pilotta, A, Sinisi, A, Zuccotti, G, Zucchini, S, Ben Skowronek, I, Birkholz, D, Bossowski, A, Hilczer, M, Korpal Szczyrska, M, Smyczynska, J, Szewczyk, L, Argente, J, Bezanilla, C, Carrascosa, A, Diaz, R, Fernandez, C, Hermoso, F, Luzuriaga, C, Martos, J, Prieto, P, Sanchez Del Pozo, J, Vela, A, Ekström, K, Nilsson, Nö, Ahmed, F, Denvir, L, Hussain, K, Johnstone, H, Mushtaq, T, Patel, L, Ramakrishnan, R, Rose, S, Shaw, N, Storr, H., Bang, P, Polak, M, Woelfle, J, Houchard, A, EU IGFD Registry Study, Group, and Perrone, Laura

Subjects
Male, Adolescent, Databases, Factual, Endocrinology, Diabetes and Metabolism, MEDLINE, EU IGFD registry, computer.software_genre, Short stature, Endocrinology, rhIGF-1 therapy, Humans, Medicine, Insulin-Like Growth Factor I, Child, Growth Disorders, Database, Height, business.industry, severe primary insulin-like growth factor-1 deficiency, Recombinant Proteins, Europe, short stature, Child, Preschool, Pediatrics, Perinatology and Child Health, Female, Observational study, medicine.symptom, Height, rhIGF-1 therapy, EU IGFD registry, short stature, severe primary insulin-like growth factor-1 deficiency, business, computer
Abstract

Background/Aims: We report data from the EU Increlex® Growth Forum Database (IGFD) Registry, an ongoing, open-label, observational study monitoring clinical practice use of recombinant human insulin-like growth factor-1 (rhIGF-1) therapy in children. Methods: Safety and effectiveness data on rhIGF-1 treatment of 195 enrolled children with growth failure were collected from December 2008 to September 2013. Results: Mean ± SD (95% CI) height velocity during first year of rhIGF-1 treatment was 6.9 ± 2.2 cm/year (6.5; 7.2) (n = 144); in prepubertal patients naïve to treatment, this was 7.3 ± 2.0 cm/year (6.8; 7.7) (n = 81). Female sex, younger age at start of rhIGF-1 therapy, and lower baseline height SDS predicted first-year change in height SDS. The most frequent targeted treatment-emergent adverse events (% patients) were hypoglycemia (17.6%, predictors: young age, diagnosis of Laron syndrome, but not rhIGF-1 dose), lipohypertrophy (10.6%), tonsillar hypertrophy (7.4%), injection site reactions (6.4%), and headache (5.9%). Sixty-one serious adverse events (37 related to rhIGF-1 therapy) were reported in 31 patients (16.5%). Conclusion: Safety and effectiveness data on use of rhIGF-1 in a ‘real-world' setting were similar to those from controlled randomized trials. Severe growth phenotype and early start of rhIGF-1 improved height response and predicted risk of hypoglycemia.

Published
2015

20. Wachstum bei Störungen und Normvarianten der Pubertät.

Author

Binder, G., Bettendorf, M., Dörr, H.-G., Hauffa, B. P., Reinehr, T., Richter-Unruh, A., Rohrer, T. R., and Wölfle, J.

Abstract

Copyright of Monatsschrift Kinderheilkunde is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2019
Full Text
View/download PDF

24. Long-term Surveillance of Children with Congenital Hypothyroidism: Data from the German Registry for Congenital Hypothyroidism (AQUAPE Hypo Dok)

Author

Ellerbroek, V. L., Bonfig, W., Doerr, H. -G., Bettendorf, M., Hauffa, B., Fricke-Otto, S., Rohrer, T., Reschke, F., Schoenau, E., Schwab, K. O., Kapelari, K., Roehl, F. -W., Mohnike, K., Holl, R. W., Ellerbroek, V. L., Bonfig, W., Doerr, H. -G., Bettendorf, M., Hauffa, B., Fricke-Otto, S., Rohrer, T., Reschke, F., Schoenau, E., Schwab, K. O., Kapelari, K., Roehl, F. -W., Mohnike, K., and Holl, R. W.

Abstract

Background: The German study group for quality assurance in pediatric endocrinology and the University of Ulm have established a software (Hypo Dok) for the documentation of longitudinal data of patients with congenital primary hypothyroidism (CH). Aim of this study was to analyse the long-term follow-up of patients with CH and to compare treatment with current guidelines. Methods/Patients: Anonymised data of 1 080 patients from 46 centres were statistically analysed. Results: Newborn screening result was available at a mean age of 7.3 days. Confirmation of the diagnosis was established at 8.4 days and therapy was started at 11 days. The average screening TSH was 180.0 mIU/L. During the first 3 months mean levothyroxine (LT4) dose was 10.7 mu g/kg/day or 186.0 mu g/m(2)/day. Weight-, BMI-and height-SDS did not differ significantly from the normal population. Only 25 % of the patients (n = 262) underwent formal EQ/IQ-testing. Their average IQ was 98.8 +/- 13.2 points. Discussion: In Germany screening, confirmation and start of treatment of CH are within the recommended time frame of 14 days. Initial LT4-doses are adequate. The auxological long-term outcome of young CH patients is normal. The implementation of standardized IQ testing has to be improved in routine patient care. Conclusion: Longitudinal data of patients with CH was analysed and compared to current guidelines. Confirmation and start of treatment are - according to the recommendations. However standardised IQ testing requires improvement.

Published
2015

28. Pleuraempyem, Zwerchfelldurchbruch und multiple Leberabszesse bei einem Kind mit Interleukin-1 Rezeptor-assoziierte Kinase (IRAK-) 4 Defekt

Author

Schöndorf, D., Von Bernuth, H., Rohrer, T., Simon, A., Schneider, G., Schäfers, H.-J., Meier, C.-M., Gortner, L., and Große-Onnebrink, J.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Ein Defekt der Interleukin-1 Rezeptor-assoziierten Kinase (IRAK-) 4 prädisponiert zu schweren, oft tödlich verlaufenden, invasiven bakteriellen Infektionen in der frühen Kindheit. Wir berichten von einem betroffenen Kleinkind mit rechtsseitigem Pleuraempyem, Zwerchfelldurchbruch und multiplen[for full text, please go to the a.m. URL], 21. Jahrestagung der Deutschen Gesellschaft für Pädiatrische Infektiologie (DGPI)

Published
2013

29. M. Alexander als Differentialdiagnose bei Erbrechen, Krampfanfällen und zunehmender Apathie am Beispiel eines 2½ Monate alten Säuglings

Author

Larsen, A., Martin, C., Mayer, S., Rohrer, T., Van Der Knaap, M., Papanagiotou, P., and Gortner, L.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Die Alexander Krankheit zählt zu den infantilen Leukodystrophien (erstmalig beschrieben 1947 durch W. S. Alexander). In Abhängigkeit vom Alter Einteilung in die neonatale, infantile, juvenile und adulte Form. Die infantile Form, die sich innerhalb der ersten 2 Lebensjahre manifestiert,[for full text, please go to the a.m. URL], Süddeutsche Tage der Kinder- und Jugendmedizin; 61. Jahrestagung der Süddeutschen Gesellschaft für Kinder- und Jugendmedizin und der Süddeutschen Gesellschaft für Kinderchirurgie und dem Berufsverband für Kinder- und Jugendärzte – Landesverband Bayern

Published
2012
Full Text
View/download PDF

30. Sinusvenenthrombose als Ursache akuter psychischer Symptomatik

Author

Martin, C, Larsen, A, Heine, S, Papanagiotou, P, Gortner, L, and Rohrer, T

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Sinusvenenthrombosen (SVT) sind mit einer Inzidenz von 7 Fällen/1 Million im Kindes- und Jugendalter selten. Häufigstes und nicht selten einziges Symptom sind subakut oder akut auftretende Kopfschmerzen. Daneben manifestiert sich die SVT mit generalisierten oder fokalen Krampfanfällen,[for full text, please go to the a.m. URL], Süddeutsche Tage der Kinder- und Jugendmedizin; 61. Jahrestagung der Süddeutschen Gesellschaft für Kinder- und Jugendmedizin und der Süddeutschen Gesellschaft für Kinderchirurgie und dem Berufsverband für Kinder- und Jugendärzte – Landesverband Bayern

Published
2012
Full Text
View/download PDF

31. Long-term Surveillance of Children with Congenital Hypothyroidism: Data from the German Registry for Congenital Hypothyroidism (AQUAPE “Hypo Dok”)

Author

Ellerbroek, V., additional, Bonfig, W., additional, Dörr, H.-G., additional, Bettendorf, M., additional, Hauffa, B., additional, Fricke-Otto, S., additional, Rohrer, T., additional, Reschke, F., additional, Schönau, E., additional, Schwab, K., additional, Kapelari, K., additional, Röhl, F.-W., additional, Mohnike, K., additional, and Holl, R., additional

Published
2015
Full Text
View/download PDF

38. Zöliakie als Risikofaktor für mikrovaskuläre Folgeerkrankungen bei Typ-1-Diabetes: Longitudinales Follow-up von 54488 Patienten aus Deutschland/Österreich im Rahmen der DPV-Initiative

Author

Wolf, J, primary, Rohrer, T, additional, Liptay, S, additional, Zimmer, K, additional, Fröhlich-Reiterer, E, additional, Marg, W, additional, Stern, M, additional, Kapellen, T, additional, Hauffa, B, additional, Wölfle, J, additional, Scheuing, N, additional, and Holl, R, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results